Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival

Molecular and Cellular Biology

Volumn 32, Issue 2, 2012, Pages 399-414

  Tan, Peck Yean ^a   Chang, Cheng Wei ^a   Chng, Kern Rei ^a   Senali Abayratna Wansa, K D ^a   Sung, Wing Kin ^a,b   Cheung, Edwin ^a,c,d  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; RAB PROTEIN; RAB3B PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BINDING SITE; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE LOCATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC REGULATION; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RECEPTOR BINDING; RECURRENT CANCER; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANDROGENS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HOMEODOMAIN PROTEINS; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RAB3 GTP-BINDING PROTEINS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84863072810     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05958-11     Document Type: Article

References (77)

1. Abate-Shen C, Shen MM. 2000. Molecular genetics of prostate cancer. Genes Dev. 14:2410-2434.
2. Abate-Shen C, Shen MM, Gelmann E. 2008. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76:717-727.
3. Asatiani E, et al. 2005. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 65:1164 -1173.
4. Beato M, Sanchez-Pacheco A. 1996. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr. Rev. 17: 587-609.
5. Bergerheim US, Kunimi K, Collins VP, Ekman P. 1991. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 3:215-220.
6. Bethel CR, et al. 2006. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 66: 10683-10690.
7. Bhatia-Gaur R, et al. 1999. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:966-977.
8. Bieberich CJ, Fujita K, He WW, Jay G. 1996. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J. Biol. Chem. 271:31779 -31782.
9. Bolton EC, et al. 2007. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21:2005-2017.
10. Bruckheimer EM, Kyprianou N. 2001. Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 142:2419-2426.
11. Carroll JS, et al. 2006. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38:1289 -1297.
12. Chang C, et al. 1995. Androgen receptor: an overview. Crit. Rev. Eukaryot. Gene Expr. 5:97-125.
13. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. 2006. Short hairpin RNAknockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res. 66:10613-10620.
14. Cheng KW, Lahad JP, Gray JW, Mills GB. 2005. Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 65:2516 -2519.
15. Cheung E, Kraus WL. 2010. Genomic analyses of hormone signaling and gene regulation. Annu. Rev. Physiol. 72:191-218.
16. Chuang AY, et al. 2007. Immunohistochemical differentiation of highgrade prostate carcinoma from urothelial carcinoma. Am. J. Surg. Pathol. 31:1246-1255.
17. Claessens F, et al. 2001. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J. Steroid Biochem. Mol. Biol. 76:23-30.
18. Compagno D, et al. 2007. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One 2:e1006.
19. Craft N, et al. 1999. Evidence for clonal outgrowth of androgenindependent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59:5030 -5036.
20. Cunha GR, et al. 1987. The endocrinology and developmental biology of the prostate. Endocr. Rev. 8:338 -362.
21. Dehm SM, Tindall DJ. 2006. Molecular regulation of androgen action in prostate cancer. J. Cell Biochem. 99:333-344.
22. Eder IE, et al. 2000. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. 7:997-1007.
23. Eder IE, et al. 2002. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther. 9:117-125.
24. Feldman BJ, Feldman D. 2001. The development of androgenindependent prostate cancer. Nat. Rev. Cancer 1:34-45.
25. Galbraith SM, Duchesne GM. 1997. Androgens and prostate cancer: biology, pathology and hormonal therapy. Eur. J. Cancer 33:545-554.
26. Gao N, et al. 2003. The role of hepatocyte nuclear factor-3 alpha (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17:1484 -1507.
27. Gary B, et al. 2004. Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am. J. Pathol. 164:1607-1614.
28. Gelmann EP. 2002. Molecular biology of the androgen receptor. J. Clin. Oncol. 20:3001-3015.
29. Grabs D, Bergmann M, Urban M, Post A, Gratzl M. 1996. Rab3 proteins and SNAP-25, essential components of the exocytosis machinery in conventional synapses, are absent from ribbon synapses of the mouse retina. Eur. J. Neurosci. 8:162-168.
30. Gurel B, et al. 2010. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am. J. Surg. Pathol. 34:1097-1105.
31. He HH, et al. 2010. Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 42:343-347.
32. He WW, et al. 1997. A novel human prostate-specific, androgenregulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43:69-77.
33. Heemers HV, Tindall DJ. 2007. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28:778-808.
34. Heinlein CA, Chang C. 2002. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23:175-200.
35. Hendrix A, et al. 2010. Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J. Natl. Cancer Inst. 102: 866-880.
36. Jemal A, et al. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58:71-96.
37. Jia L, et al. 2008. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3:e3645.
38. Keller ET, Ershler WB, Chang C. 1996. The androgen receptor: a mediator of diverse responses. Front. Biosci. 1:d59-71.
39. Korkmaz KS, et al. 2000. Full-length cDNA sequence and genomic organization of human NKX3A-alternative forms and regulation by both androgens and estrogens. Gene 260:25-36.
40. Kos L, Chiang C, Mahon KA. 1998. Mediolateral patterning of somites: multiple axial signals, including Sonic hedgehog, regulate Nkx-3.1 expression. Mech. Dev. 70:25-34.
41. Lei Q, et al. 2006. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9:367-378.
42. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. 2005. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther. 4:505-515.
43. Lin B, et al. 2009. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One 4:e6589.
44. Linhart C, Halperin Y, Shamir R. 2008. Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Res. 18:1180 -1189.
45. Lledo PM, Vernier P, Vincent JD, Mason WT, Zorec R. 1993. Inhibition of Rab3B expression attenuates Ca(2+)-dependent exocytosis in rat anterior pituitary cells. Nature 364:540 -544.
46. Lupien M, et al. 2008. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132:958 -970.
47. Magee JA, Abdulkadir SA, Milbrandt J. 2003. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 3:273-283.
48. Massie CE, et al. 2007. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 8:871- 878.
49. McKenna NJ, O'Malley BW. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465- 474.
50. Mogal AP, van der Meer R, Crooke PS, Abdulkadir SA. 2007. Haploinsufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation. J. Biol. Chem. 282: 25790-25800.
51. Nunes FD, de Almeida FC, Tucci R, de Sousa SC. 2003. Homeobox genes: a molecular link between development and cancer. Pesqui. Odontol. Bras. 17:94 -98.
52. Possner M, et al. 2008. Functional analysis of NKX3.1 in LNCaP prostate cancer cells by RNA interference. Int. J. Oncol. 32:877- 884.
53. Prescott JL, Blok L, Tindall DJ. 1998. Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35:71- 80.
54. Roy AK, et al. 1999. Regulation of androgen action. Vitam. Horm. 55: 309-352.
55. Samuel S, Naora H. 2005. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur. J. Cancer 41: 2428-2437.
56. Sciavolino PJ, et al. 1997. Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Dev. Dyn. 209:127-138.
57. Shah N, Sukumar S. 2010. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 10:361-371.
58. Stanfel MN, Moses KA, Schwartz RJ, Zimmer WE. 2005. Regulation of organ development by the NKX-homeodomain factors: an NKX code. Cell Mol. Biol. 51(Suppl.):OL785-OL799.
59. Takayama K, et al. 2007. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26:4453- 4463.
60. Takayama K, et al. 2009. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res. 69: 137-142.
61. Tan SK, et al. 2011. AP-2gamma regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO. J. 30: 2569-2581.
62. Trapman J, Brinkmann AO. 1996. The androgen receptor in prostate cancer. Pathol. Res. Pract. 192:752-760.
63. Trapman J, et al. 1994. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res. 54: 6061-6064.
64. Vocke CD, et al. 1996. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 56:2411-2416.
65. Wang D, et al. 2011. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474:390 -394.
66. Wang JS, Wang FB, Zhang QG, Shen ZZ, Shao ZM. 2008. Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol. Cancer Res. 6:372-382.
67. Wang Q, et al. 2007. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27:380-392.
68. Wang X, et al. 2009. Aluminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461:495-500.
69. Weber E, Jilling T, Kirk KL. 1996. Distinct functional properties of Rab3A and Rab3B in PC12 neuroendocrine cells. J. Biol. Chem. 271: 6963-6971.
70. Wright ME, Tsai MJ, Aebersold R. 2003. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol. Endocrinol. 17:1726 -1737.
71. Xu H, et al. 2010. A signal-noise model for significance analysis of ChIPseq with negative control. Bioinformatics 26:1199 -1204.
72. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. 2005. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int. 5:8.
73. Yu J, et al. 2010. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443-454.
74. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgenrefractory prostate cancer cells. Cancer Res. 62:1008 -1013.
75. Zhang H, et al. 2008. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res. 68:8770-8778.
76. Zhang Z, Chang CW, Goh WL, Sung WK, Cheung E. CENTDIST: discovery of co-associated factors by motif distribution. Nucleic Acids Res., in press.
77. Zhu ML, Kyprianou N. 2008. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 15: 841-849.